alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 73, Number 18 (Monday, January 28, 2008)]
[Notices]
[Page 4882]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 08-306]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Allergy, Immunology, and Transplantation 
Research Committee.
    Date: February 12-13, 2008.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Doubletree Hotel, 1515 Rhode Island Avenue, NW., 
Washington, DC 20005.
    Contact Person: Katrin Eichelberg, PhD, Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616, 
Bethesda, MD 20892, (301) 496-0818, <a href="/cdn-cgi/l/email-protection#7219171b111a171e10170015321c1b131b165c1c1b1a5c151d04"><span class="__cf_email__" data-cfemail="fe959b979d969b929c9b8c99be90979f979ad0909796d0999188">[email protected]</span></a>.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: January 17, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 08-306 Filed 1-25-08; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
AGENDA 

Advisory Board on Radiation and Worker Health 

Teleconference Meeting of the 

Subcommittee on Dose Reconstruction Review (SDRR)

January 19, 2022 

Teleconference Phone: 866-659-0537, Participant Code: 9933701# 

10:30 a.m. Eastern Time

Welcome and roll-call 

DISCUSSION

– Review Cases from Set 29

Facilities that may be covered: Nevada test Site, Oak Ridge Institute for Science 

Education, Rocky Flats Plant, Idaho National Laboratory, Y-12 Plant, Clarksville 

Modification Center, Pantex Plant, Oak Ridge National Laboratory (X-10), Albuquerque 

Operations Office, General Atomics, Area IV of the Santa Susanna Field Laboratory, 

Oak Ridge Gaseous Diffusion Plant (K-25), Savannah River Site (SRS), Hanford 

– Review Cases from Set 30

Facilities that may be covered: SRS, X-10, Y-12 Plant, General Steel Industries

4:00 p.m. Adjourn
AGENDA

Advisory Board on Radiation and Worker Health 

Teleconference Meeting of the

Subcommittee on Dose Reconstruction Review

October 29, 2014

Conference Call Number: 1-866-659-0537

Participant Pass Code: 9933701

10:30 a.m. Eastern Time

Welcome and roll-call

DISCUSSION

Case Reviews Issue Resolution

• Sets 10-13, remaining cases (Hanford, Mound Plant, Oak Ridge National 

Laboratory, Y-12, K-25, Lawrence Livermore National Laboratory, Pacific 

Proving Grounds, Hooker Electrochemical, Simonds Saw and Steel, 

Bethlehem Steel, Weldon Spring, W.R. Grace, Westinghouse, International 

minerals and Chemical Corporation, Koppers Co., Bridgeport Brass, 

Uranium Mill in Monticello, General Steel Industries, and DuPont 

Deepwater Works.)

Plans for completing review of Sets 10-13 (if not completed)

Summarizing review results for Board report

Status of review responses for Sets 14 – 18

Updates on NIOSH and SC&A Blind Reviews

5:00 p.m. Adjourn
=

rel .
The Consortium for Risk Evaluation with Stakeholder Participation
(CRESP Headquarters:
einem 168 20 @4
oa ee a 4s |
Environmental and Occupationa! Health Sciences Institute University of Washington, Department of Environmental Health
'UMDNJ-Robert Wood Johnson Medical SchooVRutgers University 4225 Roosevek Way NE, Suite 100
170 Frelinghuysen Road, Piscataway, New Jersey 08854 ‘Seattle, Washington 98105-6099
Phone: 732-445-0200 Fax: 732-445-0131 Phone: 206-616-4874 Fax 206-616-4875

April 17, 2001

Larry J. Elliott, MSPH, CIH

Acting Director, Office of Compensation
Analysis and Support

National Institute of Occupational
Safety and Health

Roberta A. Taft Laboratories

4676 Columbia Parkway

Cincinnati, OH 46226-1998

Dear Mr. Elliott:

Thank you for your letter of April 11, concerning the development of a new occupational
illness compensation program. Although I have limited personal expertise in
compensation matters, I have noted with interest a report by Wakeford et al to the effect
that a probability of causation method has been used successfully for compensating
nuclear industry workers in the UK (Wakeford, R., Antell, B.A., and Leigh, W.J.: A
review of probability of causation and its use in a compensation scheme for nuclear
industry workers in the United Kingdom. Health Physics 74: 1-9, 1998).

If can do anything to be of help to you in developing the program, please don’t hesitate
to call on me.

Sincerely,

Chri, @

Arthur C. Upton, M.D.

RUTGERS uD)

University of Medicine and Dentistry
‘The State University of New Jersey Of New Jersey
Rutgers Robert Wood Johnson Medica! Schoo! ‘The University of Washington
Draft Agenda 

Subcommittee for 

Dose Reconstruction and Site Profile Reviews 

The Westin St. Louis 

811 Spruce Street 

St. Louis, Missouri 63102
 

Phone: 314-621-2000 

Fax: 314-552-5700 

Wednesday, August 24, 2005 – 10:00 a.m. – 5:00 p.m. 

 Bethlehem Site Profile 

 Selection of 4th Round of 20 Dose Reconstructions 

 Mallinckrodt Site Profile Review 

 Discussion of Candidate Site Profiles for Review by SC&A 

NOTE: NIOSH Staff will be available during the Advisory Board Meeting 

to provide individual claim information 

***Agenda items are subject to change as priorities dictate*** 
 

 

 

 

 

 

 

Draft Agenda 

Advisory Board on Radiation and Worker Health – Meeting 32 

The Westin St. Louis 

811 Spruce Street 

St. Louis, Missouri 63102
 

Phone: 314-621-2000 

Fax: 314-552-5700 

Thursday, August 25, 2005 

8:30 a.m. - 8:45a.m Welcome and Opening Dr. Paul Ziemer, Chair 

 Comments Dr. Lew Wade, Executive Secretary 

8:45 p.m. – 11:30 p.m. Reports from Subcommittee: 

Bethlehem Site Profile 

 Selection of 4th Round of 20 Dose Reconstructions 

Discussion of Candidate Site Profiles 

 For Review by SC&A 

11:30 a.m. – 1:00 p.m.	 Lunch Break 

1:00 p.m. – 3:00 p.m. Closed Session - Dr. Lew Wade 

Work Tasks for SC&A Contract 

 For Next Year 

3:00 p.m – 3:30 p.m	 Break 

3:30 p.m. – 5:00 p.m. Report from Subcommittee: 

 Mallinckrodt Site Profile Review 

5:00 p.m. Adjourn 

7:00p.m. – 8:30 p.m. General Public Comment 

NOTE: NIOSH Staff will be available during the Advisory Board Meeting 

to provide individual claim information 

***Agenda items are subject to change as priorities dictate*** 
 

 

 

 

 

 

 

 

 

 

 

 

 

Draft Agenda 

Advisory Board on Radiation and Worker Health – Meeting 32 

The Westin St. Louis 

Friday, August 26, 2005 

8:30 a.m. – 8:45 a.m. 

8:45-a.m. – 10:00 a.m. 

10:00 a.m. – 10:20 a.m. 

10:20 a.m. – 12:00 p.m. 

12:00 p.m. – 1:30 p.m. 

1:30 p.m. – 2:45 p.m. 

2:45 p.m. – 3:00 p.m. 

3:00 p.m. – 3:45 p.m. 

3:45 p.m. – 4:30 p.m. 

811 Spruce Street 

St. Louis, Missouri 63102
 

Phone: 314-621-2000 

Fax: 314-552-5700 

Welcome and Opening 

 Comments 

Mallinckrodt SEC Presentations 

Break 

Board Discussion – 

 Mallinckrodt SEC Petition 

Lunch 

Board Discussion – 

 Mallinckrodt SEC Petition 

Break 

Board Discussion – 

 Heads-up on SEC Petition 

 Under § 83.14 of the SEC rule 

 42 CFR pt. 83) 

Board Discussion – 

Policy on SC&A Capitol Hill Visits 

Dr. Paul Ziemer, Chair 

 Dr. Lew Wade, Executive Secretary 

NIOSH 

Petitioners 

Dr. Paul Ziemer, Chair 

Dr. Paul Ziemer, Chair 

Mr. Larry Elliott 

Dr. Paul Ziemer, Chair 

4:30 p.m. Adjourn 

NOTE: NIOSH Staff will be available during the Advisory Board Meeting 

to provide individual claim information 

***Agenda items are subject to change as priorities dictate***
Moody National REIT I, Inc. 10-Q


EXHIBIT 32.2




CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO SECTION 906 OF THE


SARBANES-OXLEY ACT OF 2002




Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and in connection with the Quarterly Report on Form 10-Q of Moody National REIT I, Inc. (the “Company”) for the period ended September 30, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, the Chief Financial Officer and Treasurer of the Company, certifies, to his knowledge, that:




(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and




(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.








Date: November 15, 2010




/s/ Robert W. EngelRobert W. EngelChief Financial Officer and Treasurer(Principal Financial and Accounting Officer)
EXHIBIT 32





CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Quarterly Report of Musician’s Exchange (the “Company”) on Form 10-Q for the period ended March 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel Van Ness, President and Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:





1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.











/s/Daniel Van NessDaniel Van NessPresident andPrincipal Accounting OfficerMay 13, 2010
AGENDA

Advisory Board on Radiation and Worker Health 

Teleconference of the 

Lawrence Berkeley National Laboratory WG 

November 25, 2019

3:00 p.m. (Eastern Daylight Time)

Conference Call Number: 1-866-659-0537

Participant Pass Code: 9933701

1. Welcome and roll-call/introductions ............................................... Ted Katz

 

 

2. Discussion (as needed) of any closed findings/observations ... Paul Ziemer, WG Chair 

3. Overview of current DCAS work underway ...................... Megan Lobaugh, DCAS 

4. Summary/discussion of current responses to SC&A review of internal dose 

methods.................................................................. Megan Lobaugh, DCAS

5. Action items and plans for December Board meeting presentation(s) 

............................................................................. Paul Ziemer, WG Chair 

6. Adjourn
National Institute for Occupational Safety and Health

NIOSH Program Update

Stuart Hinnefeld, CHP

Director

Division of Compensation Analysis and Support 

Meeting of the Advisory Board on Radiation and Worker Health

April 2018 | Oak Ridge, TN
Updates

— Joint Outreach Task Group met in Ames, Iowa 

about Special Exposure Cohort class addition

— Authorized representative workshop set for May in 

Kennewick, WA

— Budget
Cases

— 48,835 cases to NIOSH from Department of 

Labor (DOL)

– 1,238 at NIOSH for dose reconstruction (DR)

– 827 administratively closed

— 46,770 returned to DOL

Note: All data as of March 31, 2018
Cases cont.

—41,763 submitted with DR to DOL

— 1,538 pulled from DR by DOL

— 3,469 pulled for SEC
Cases cont.

— 1,238 active cases at NIOSH for DR

– 341 in DR process

– 254 initial draft DR reports with claimants

– 643 cases in DR development
PC Summary

—41,763 DRs sent back for final adjudication

— 11,636 PC ≥ 50%

— 30,127 PC < 50%
DOE records Requests

—225 outstanding

— 6 more than 60 days
Summary of first 20,000 DRs cont.

—19,568 claims at DOL

– 769 pulled for DOL issues 

– 2,062 pulled for SEC 

—16,737 submitted with DR
Summary of first 20,000 DRs cont.

—399 claims at NIOSH

— 357 administratively closed 

– 14 with claimants (0 initial, 14 DOL returns)

– 28 DRs in process (1 initial, 27 DOL returns) 

— 33 claim numbers deleted
Questions
[Federal Register Volume 73, Number 5 (Tuesday, January 8, 2008)]
[Notices]
[Page 1325]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 08-18]


-----------------------------------------------------------------------

COMMISSION OF FINE ARTS


Notice of Meeting

    The next meeting of the U.S. Commission of Fine Arts is scheduled 
for January 17, 2007, at 10 a.m. in the Commission's offices at the 
National Building Museum, Suite 312, Judiciary Square, 401 F Street, 
NW., Washington, DC 20001-2728. Items of discussion may include 
buildings, parks and memorials.
    Draft agendas and additional information regarding the Commission 
are available on our Web site: http://www.cfa.gov. Inquiries regarding 
the agenda and requests to submit written or oral statements should be 
addressed to Thomas Luebke, Secretary, U.S. Commission of Fine Arts, at 
the above address, or call 202-504-2200. Individuals requiring sign 
language interpretation for the hearing impaired should contact the 
Secretary at least 10 days before the meeting date.

    Dated in Washington, DC, December 31, 2007.
Thomas Luebke,
Secretary.
[FR Doc. 08-18 Filed 1-7-08; 8:45 am]
BILLING CODE 6330-01-M
Exhibit 32.1

                    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
                       PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Green Star Mining Corp. (the
"Company") on Form 10-Q for the period ending August 31, 2009 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Nan E.
Weaver, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.
ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:

     (1)  The Report fully complies with the requirements of section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.

IN WITNESS WHEREOF, the undersigned has executed this certification as of the
1st day of October, 2009.


/s/ Nan E. Weaver
---------------------------
Chief Executive Officer
**Exhibit 32.1
**Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

 

 

 

In connection with the Annual Report of Cannabis Science, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dr. Robert Melamede, Chief Executive Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date:  April 15, 2011

 

 

*/s/ Dr. Robert Melamede*Dr. Robert MelamedePresident and Chief Executive Officer                                   

 **
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Commodity Futures Trading Commission

# Time and Date:

11 a.m., Friday, February 15, 2008. 

# Place:

1155 21st St., NW., Washington, DC, 9th Floor Commission Conference Room. 

# Status:

Closed. 

# Matters to be Considered:

Surveillance matters. 

# Contact Person for more Information:

Sauntia S. Warfield, 202-418-5084. 

David A. Stawick, 

Secretary of the Commission.

[FR Doc. 08-192 Filed 1-16-08; 10:06 am] 

BILLING CODE 6351-01-P
Exhibit
32.1




CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002




In
connection with the Quarterly Report of Pansoft Company Limited (the “Company”)
on Form 10-Q for the period ending September 30, 2008, as filed with the
Securities and Exchange Commission on November 14, 2008 (the “Report”), I,
Hugh Wang, Chairman of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as
adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002,
that:




1. The
Report fully complies with the requirements of Section 13(a) or 15(d) of
the Exchange Act of 1934; and




2. The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.




November
      14, 2008
            /s/
      Hugh WangHugh
      WangChairman
      (Principal ExecutiveOfficer)
A96A1109.

#### SMITH v. THE STATE.

(471 SE2d 591)

Decided April 19, 1996

*Howard J. Weintraub,*for appellant.

*Louise T. Hornsby, Solicitor, Marcelle A. Castillo, Assistant Solicitor,*for appellee.

Blackburn, Judge.

On July 19, 1995, Graham Smith was arrested for driving under the influence of alcohol, and an Administrative License Suspension proceeding was initiated. Because the arresting officer failed to appear at the Administrative License Suspension hearing, the proposed suspension was rescinded. On August 29, 1995, Smith filed his plea in bar based upon double jeopardy to stop the criminal prosecution of the DUI charge. The trial court denied Smith’s plea.

On appeal, Smith contends that the trial court erred when it held that the State’s criminal prosecution, following an Administrative License Suspension action, does not constitute double jeopardy. Smith’s position was decided adversely to him in *Nolen v. State,*218 Ga. App. 819 (463 SE2d 504) (1995), and we decline to reconsider our holding therein. See also *Jackson v. State,*218 Ga. App. 677 (462 SE2d 802) (1995).

*Judgment affirmed.*

*Beasley, C. J, and Birdsong, P. J., concur.*
Exhibit 31.1

CERTIFICATION

I, Douglas J. Mattscheck, Chief Executive Officer and President of AGY Holding Corp., certify that:

1. I have reviewed this quarterly report on Form 10-Q of AGY Holding Corp. (the Registrant);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my
knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods
presented in this report;

4. The Registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Registrant and have:

a. Designed such disclosure controls and
procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

b. Evaluated the effectiveness of the Registrants
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c. Disclosed in this report any change in the Registrants internal control over financial reporting that occurred during the Registrants most
recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrants internal control over financial reporting; and

5. The Registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrants auditors and the audit committee of
Registrants board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrants ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrants internal control
over financial reporting.

Date: November 12, 2008



|                                                                                         
|-----------------------------------------------------------------------------------------
|/s/ Douglas J. Mattscheck                                                                
|Douglas J. Mattscheck Chief Executive Officer and
President (Principal Executive Officer)